Login to Your Account



Biopharmas get off to a good start with drug approvals in Q1

By Peter Winter and Karen Carey
Editor and Analyst

Monday, April 16, 2018

One of the metrics used to gauge the industry's progress is the number of new medicines that receive regulatory approval annually. The returns from the first quarter indicate that the innovation engine is in good shape and biopharma companies appear to be on pace to match the totals they achieved in the past couple of years. 

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription